United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Pfizer Inc.  PFE are making a large move higher Tuesday. But the stock has run into resistance.

Stock Of The Day: Is Pfizer About To Break Out? Expect A New Uptrend If Resistance Breaks

Pfizer Inc. (NYSE:PFE ) Full-Year 2025 Financial Guidance Conference Call December 17, 2024 8:30 AM ET Company Participants Francesca DeMartino - Chief IRO and SVP Albert Bourla - Chairman and CEO David Denton - CFO Conference Call Participants Chris Schott - JPMorgan Geoff Meacham - Citibank Steve Scala - TD Securities Tim Anderson - Bank of America Chris Shibutani - Goldman Sachs Trung Huynh - UBS Vamil Divan - Guggenheim Evan Seigerman - BMO Capital Markets Operator Good day, everyone, and welcome to Pfizer's Analyst and Investor Call to Review Full Year 2025 Financial Guidance. Today's call is being recorded.

Pfizer Inc. (PFE) Full-Year 2025 Financial Guidance Conference Call (Transcript)

Pfizer (PFE) shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.

Pfizer Stock Rises as 2025 Outlook in Line With Expectations

Teva Pharmaceutical

Pharma stocks Pfizer Inc (NYSE:PFE) and Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are in the spotlight today.

2 Pharma Stocks to Watch: Pfizer, Teva Pharmaceutical

Pfizer stock jumped early Tuesday after the pharma giant issued a mixed outlook for 2025. Revenue missed forecasts, while earnings beat some.

Pfizer Stock Jumps On Mixed, But 'Marginally Encouraging,' 2025 Outlook

Pfizer Inc (NYSE:PFE, ETR:PFE) shares ticked up on Tuesday after the pharmaceutical giant appeared to offer relief for investors with guidance for the coming year. Revenue should grow by up to 5% next year to between $61.0 billion and $64.0 million, Pfizer signalled in a statement on Tuesday.

Pfizer ticks up as expectation-matching guidance relieves investors

On Tuesday, Pfizer Inc. PFE released its full-year 2025 financial guidance, projecting revenues between $61.0 billion and $64.0 billion compared to a consensus of $63.28 billion.

Pfizer Does Not Anticipate Material Changes To US Vaccine Policy From The Incoming Administration In 2025

Pfizer forecast 2025 revenue and earnings in line with market expectations, despite a $1 billion hit from the redesign of federal drug benefits.

Pfizer Sees 2025 Revenue in Line With Wall Street Views

The company anticipates adjusted earnings of between $2.80 and $3 a share in 2025. Analysts had been expecting adjusted earnings of $2.86.

Pfizer Stock Rises as Drug Giant Sees 2025 Revenue of $61 Billion to $64 Billion

Drugmaker Pfizer on Tuesday said it was expecting its 2025 profits to be nearly in line with Wall Street expectations as it seeks to fend off criticism over its turnaround strategy from activist hedge fund Starboard Value.

Pfizer forecasts 2025 profit in line with expectations

NEW YORK--(BUSINESS WIRE)--Pfizer 2025 Financial Guidance press release.

Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance

Intuitive Surgical

What's the hottest S&P 500 stock of 2024? Palantir Technologies (PLTR -0.42%) is the hands-down winner.

Prediction: 2 Stocks That'll Be Worth More Than Palantir 5 Years From Now

Cigna

CVS Health

Eli Lilly

UnitedHealth Group

Shares of health insurers operating pharmacy benefit managers fell on Monday after U.S. President-elect Donald Trump called them middlemen who drive up costs and said he plans to eliminate their role.

Insurer stocks fall after Trump says 'we're going to knock out the middleman'

Pfizer Inc. PFE will conduct an investor call on Tuesday to provide full-year 2025 financial guidance.

What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?

Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling value play. Despite revenue declines and potential regulatory risks, Pfizer remains a cash-generating machine with strong liquidity and a robust drug pipeline. Pfizer's operational improvements, debt reduction, and consistent dividend growth signal a turnaround, making it an attractive investment at current depressed levels.

Pfizer: Lowest Levels In A Decade Is An Opportunity With A Dividend Yield Exceeding 6.5%

Viking Therapeutics

Vertex Pharmaceuticals

Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need their medications, so regardless of the economic environment, these companies generally see at least stability in revenue.

Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030

Pfizer's stock has become appealing due to irrational vaccine fears. Market fears about RFK Jr.'s potential anti-vaccine stance are likely overblown, as neither he nor Trump have indicated plans to block vaccines. Pfizer's strong growth in oncology and specialty care, along with cost-cutting measures, suggest the stock is undervalued at below 10x EPS guidance.

Pfizer: Irrational Anti-Vaccine Fear

With a market capitalization of more than $143 billion today, Pfizer (PFE 0.83%) stock won't make anyone into a millionaire unless they're willing to commit a large amount of capital and then hold the stock for a very long period of time, reinvesting all the dividends they receive along the way. Big pharma businesses simply don't grow quickly enough to deliver investors the massive returns that are necessary to generate millions from a humble starting sum.

Is Pfizer a Millionaire Maker?

November was an interesting month for pharmaceutical companies in general. President-elect Trump officially announced that Robert F.

Reader Mailbag: Is Pfizer (PFE) a Good Deal Right Now?

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company's common stock to $0.43 for the first-quarter 2025 dividend, payable March 7, 2025, to holders of the Common Stock of record at the close of business on January 24, 2025. The first-quarter 2025 cash dividend will be the 345th consecutive quarterly dividend paid by Pfizer. “Our decision to increase our quarterly dividend underscores our.

Pfizer Declares First-Quarter 2025 Dividend

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) today announced results from the Phase 3 PATINA trial demonstrating that the addition of IBRANCE® (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epiderm.

Pfizer's IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer

In the latest trading session, Pfizer (PFE) closed at $25.23, marking a -1.33% move from the previous day.

Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know

Pfizer's share price struggles despite a strong asset portfolio and $10 billion annual R&D investment, with significant Seagen acquisition integration ongoing. Q3 2024 results show 32% YoY revenue increase, driven by COVID-19 products and 14% growth excluding one-time impacts, with improved margins. Oncology revenue up 31% YoY, promising pipeline advancements, and strong vaccine portfolio, including potential Lyme disease vaccine and promising Cachexia treatment.

Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns

I upgrade Pfizer to "Strong Buy" due to its undervaluation, strong pipeline, and operational growth despite recent stock price declines. Pfizer's Q3 FY2024 earnings showed significant revenue and EPS growth, driven by COVID-19 therapies and oncology products, indicating robust strategic execution. The company's diversified portfolio, including successful vaccines and promising new drugs, positions it for long-term success and potential stock price re-rating.

Pfizer Stock: A Golden Buying Opportunity (Rating Upgrade)

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:30 a.m. EST on Tuesday, December 17, 2024. The purpose of the call is to provide Pfizer's full-year 2025 financial guidance. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning tod.

News for Pfizer Stock (PFE)